Staff Investigators

拟设两名工作人员调查员，均担任临床研究副协理主任， Research. Afshin Dowlati博士，肺癌新疗法开发专家， Sweetenham是淋巴瘤治疗专家，都是有成就的临床研究人员， 相当大的领导能力，以协调临床试验研究，强调制药商发起的 努力作为研究人员，他们将有集中的时间致力于临床试验开发， 监督，特别强调跨科学项目的、涉及 案例CCC临床试验疾病团队。作为工作人员调查员，他们将享有突出地位， 有权协助研究者制定和设计方案，并进行有效、安全的管理， 在药物开发的早期阶段有高度的质量保证。

Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical Research. Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated efforts. As staff investigators, they will have focused time to devote to clinical trials development and oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and authority to assist investigators in protocol development and design, and in efficient, safe management with a high degree of quality assurance during early phase drug development.